ESLA
Estrella Immunopharma, Inc.
Estrella Immunopharma, Inc. (ESLA) is currently in a downtrend, trading below both the 50-day and 200-day moving averages. RSI is at 29.8 (oversold), with 0/3 trend checks passing.
ESLA with MA50 and MA200
Key levels & signals
Estrella Immunopharma, Inc. (ESLA) currently looks weaker on the chart and is not showing much trend strength. The latest available price is $0.77, and 0 of 3 core trend checks are currently passing. Price is trading below the 50-day moving average by 28.6% and below the 200-day moving average by 45.8%.
ESLA currently has an RSI reading of 29.8, which suggests weaker momentum and a more oversold condition. Some traders may review this kind of setup for a rebound or buy-the-dip idea, but oversold readings by themselves do not guarantee a reversal.
For traders reviewing ESLA next, the main question is whether weakness is starting to stabilise or whether the chart still looks vulnerable to further downside. Some traders may watch for bounce attempts, but others will want to see stronger proof that the trend is improving before treating the stock as a cleaner setup.
About Estrella Immunopharma, Inc.
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California.
ESLA shares outstanding over time
Tracking total shares outstanding is one way to spot dilution — a rising line means the company has issued more shares (stock-based compensation, secondary offerings, convertible debt), which spreads the same earnings and ownership across more shares. A falling line usually reflects buybacks.
Learn the indicators behind this page
More stock opportunities
Common questions about ESLA
Is this page a buy or sell recommendation?
No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.
Why can a stock look bullish and overbought at the same time?
Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.
What should I do next after reading this page?
Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.